Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | ATP6V1B1 | P15313 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28181946 | 0.77 | CYP2A6 (0.69) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL2458425 | 0.73 | CYP2A6 (0.69) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL2458423 | 0.73 | CYP2A6 (0.69) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL9741433 | 0.73 | LOXL2 (0.43) | IDO1NPC1RAB9A | |
| SCHEMBL1177092 | 0.71 | CYP2A6 (0.60) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL1877335 | 0.70 | CYP2A6 (0.55) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL1877333 | 0.70 | CYP2A6 (0.55) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL15359580 | 0.70 | CYP2A6 (0.64) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL7989701 | 0.70 | CYP2A6 (0.50) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL710067 | 0.69 | NPC1 (0.55) | CYP2A6MAPTIDO1NPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160374983-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | LI-WEBER MIN (DE) | 2016-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374983-A1 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER | BAD, BID, CASP2 | CYP2A6 2135/4885MAPT 4470/4885IDO1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.